-
CureVac, GSK Partner Release Data On Influenza Vaccine Study
Thursday, April 4, 2024 - 12:18pm | 543Read More...CureVac N.V. (NASDAQ:CVAC) released interim data on Thursday, April 4, from studies it conducted on its seasonal influenza vaccine candidate. The study is part of a collaboration with GSK Plc (NYSE:GSK). The multivalent candidate was selected from a comprehensive Phase 1 part, which tested vaccine...
-
Canadian Government, Sanofi To Build C$925M Flu Vaccine Facility In Toronto
Wednesday, March 31, 2021 - 11:57am | 253Read More...Sanofi SA (NASDAQ: SNY) is dropping a major investment into its supply chain by shelling C$925 million to build a new manufacturing facility in Toronto. The new facility will be operational by 2026 and provide additional antigen and filling capacity for Fluzone, a high-dose flu...
-
Novavax The Downtrodden Finally Finds A New Bull At Citi
Tuesday, October 31, 2017 - 10:00am | 459Read More...Analysts at Citi turned bullish on Novavax, Inc. (NASDAQ: NVAX), a small-cap clinical-stage vaccine company. The firm's Joel Beatty upgrades Novavax's stock rating from Neutral to Buy with a price target boosted from $1.10 to $1.60. Novavax's phase 1 and phase 2 data for its flu vaccine called...
